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Abstract: Publication bias occurs when results of published studies are systematically different 
from results of unpublished studies. The term “dissemination bias” has also been recommended 
to describe all forms of biases in the research-dissemination process, including outcome-reporting 
bias, time-lag bias, gray-literature bias, full-publication bias, language bias, citation bias, and 
media-attention bias. We can measure publication bias by comparing the results of published 
and unpublished studies addressing the same question. Following up cohorts of studies from 
inception and comparing publication levels in studies with statistically significant or “positive” 
results suggested greater odds of formal publication in those with such results, compared to those 
without. Within reviews, funnel plots and related statistical methods can be used to indicate 
presence or absence of publication bias, although these can be unreliable in many circumstances. 
Methods of avoiding publication bias, by identifying and including unpublished outcomes and 
unpublished studies, are discussed and evaluated. These include searching without limiting by 
outcome, searching prospective trials registers, searching informal sources, including meeting 
abstracts and PhD theses, searching regulatory body websites, contacting authors of included 
studies, and contacting pharmaceutical or medical device companies for further studies. Adding 
unpublished studies often alters effect sizes, but may not always eliminate publication bias. 
The compulsory registration of all clinical trials at inception is an important move forward, 
but it can be difficult for reviewers to access data from unpublished studies located this way. 
Publication bias may be reduced by journals by publishing high-quality studies regardless of 
novelty or unexciting results, and by publishing protocols or full-study data sets. No single step 
can be relied upon to fully overcome the complex actions involved in publication bias, and 
a multipronged approach is required by researchers, patients, journal editors, peer reviewers, 
research sponsors, research ethics committees, and regulatory and legislation authorities.
Keywords: publication bias, reporting bias, research-dissemination bias, evidence synthesis, 
systematic review, meta-analysis
Introduction
Published literature is the main source of evidence for making clinical and health-
policy decisions. The number of published studies has increased dramatically over 
time.1 It was estimated that over US$100 billion investment in biomedical research 
worldwide generated 1 million research publications per year.2 However, there are 
still concerns that many completed research studies have not been formally published. 
We may simultaneously have two paradoxical problems: information overload due 
to an overwhelming volume of literature, and inaccessibility of results from relevant 
studies. Particularly, if results of published studies are systematically different from 
those of unpublished studies, published studies will not be a valid representation of 
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all studies conducted, and the evidence base for clinical and 
health-policy decisions will be questionable.3
In this article, we provide a comprehensive review of 
publication bias. We first consider the question about what 
publication bias is. Then, we discuss methods to detect and 
avoid publication bias. Our discussion is based on a previous 
report on publication bias,3 complemented and updated with 
recently published key studies.
What is publication bias?
Concepts and definitions
The term “file-drawer problem” was used by Rosenthal in 
1979 to describe the fact that many completed studies have 
never been published.4 Publication of a study in a peer-
reviewed journal is usually considered as being formally 
published. It has been reported that about 50% of completed 
studies may remain unpublished.3,5,6 Publication bias occurs 
when the publication of studies depends on the nature and 
direction of the results, so that published studies may be 
systematically different from those of unpublished studies.7 
In general, studies with statistically significant or positive 
results are more likely to be published than those with 
nonsignificant or negative results.3
Publication bias has been recognized as a problem in 
medical research for many years. The first article with the 
term “publication bias” that could be identified by search-
ing PubMed was published in 1979 about the association 
between testicular size and abnormal karyotypes.8 Since 
then, the number of references that are potentially relevant 
to publication bias has considerably increased (Figure 1). 
This increase in the number of relevant studies on publication 
bias may reflect the increased awareness of publication and 
related biases.
Dissemination of research results is a complex process 
(Figure 2). In addition to journal papers, study results may 
be presented at relevant conferences, submitted to medicine 
regulatory authorities, and in clinical study reports to trial 
sponsors.3 Results presented at conferences are usually only 
available in abstract form. Clinical study reports contain 
much more detailed information on methodology and a 
wider selection of outcomes – fuller results.9 Data submitted 
to regulatory authorities are also important sources of trial 
results. However, clinical study reports and data submit-
ted to regulatory authorities have limited accessibility, and 
their use for making evidence-based decisions may not be 
as straightforward as results published in peer-reviewed 
journals. Therefore, results of trials that are not published 
in peer-reviewed journals are conventionally considered as 
being “unpublished.”
The accessibility of trial results depends on whether, 
when, where, and in what format results of a study are 
published.10 Empirical evidence indicated the existence of 
biases throughout the whole research-dissemination process, 
including time-lag bias, outcome-reporting bias, gray- literature 
bias, full-publication bias, language bias, citation bias, and 
media-attention bias.3 The term “research-dissemination 
profile” has been recommended to describe the extent to which 
study results are accessible, which ranges from completely 
inaccessible to fully accessible.11 Dissemination bias occurs 
when the dissemination profile of research is associated with 
the direction and/or nature of studies’ results.3
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Figure 1 Number of references relevant to publication bias identified from searching 
PubMed. Search was conducted on January 28, 2013 using keywords “publication 
bias” or “reporting bias” or “dissemination bias.”
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Figure 2 Generation and dissemination of results of clinical trials: a complex process.
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Convincing evidence from recent high-quality empirical 
studies has confirmed the existence of outcome-reporting 
bias.12–14 Outcome-reporting bias occurs when “positive” 
outcomes are more likely to be reported than “negative” 
outcomes in studies with multiple outcomes. Therefore, in 
contrast to publication bias due to the nonpublication of whole 
studies, outcome-reporting bias due to selective reporting of 
outcomes by authors in published studies has been referred 
to as “within-study publication bias.”15 Furthermore, negative 
results being misinterpreted and reported as positive results 
in published clinical trials is also prevalent.16,17
Causes of publication bias
Bias may be introduced intentionally or unintentionally, 
consciously or unconsciously, into the process of research 
dissemination.3,18 The dissemination profile of research 
may be influenced by investigators, study sponsors, peer 
reviewers, and journal editors. According to surveys of 
investigators, the main reasons for nonpublication of com-
pleted studies included lack of time or low priority (34.5%), 
unimportant results (19.6%), and journal rejection (10.2%).3 
Therefore, the nonpublication of studies was usually due to 
investigators’ failure to write up and submit to journals when 
the results were considered to be negative or nonsignificant. 
Publication in peer-reviewed journals is an essential require-
ment for academic researchers. It is interesting to understand 
why investigators often failed to submit studies for journal 
publications. One study found that many researchers may 
have results from multiple studies that could be publishable, 
and they usually focused on “wonderful results” and had no 
time for “negative results.”19 We know that the preparation 
of manuscripts for journal publication is a time-consuming 
process. To a certain extent, experienced researchers may be 
able to predict what results are more likely to be accepted 
for publication in high-impact journals. Such results may 
typically be statistically significant, or considered important 
or positive.
Many clinical studies are sponsored by pharmaceutical 
companies, and commercial interests may determine the 
dissemination profile of a study. Many cases have been 
described in which the publication of studies with negative 
results has been suppressed by pharmaceutical companies.3,20 
For example, a company-sponsored study investigated the 
effect of deferiprone for the prevention of iron toxicity in 
patients with thalassemia and found that the drug might 
be harmful. Legal action was taken by the company in 
order to stop the publication of the results.21,22 In many 
cases, “negative” results submitted to medicinal regulatory 
authorities have never been published in peer-reviewed 
journals.23–25 Since 2000, the complete suppression of pub-
lication of clinical studies may have become more difficult, 
at least partly due to the public awareness of detrimental 
consequences of publication bias and the development of 
trial registration. However, biased selection of outcomes 
reported in publications is still prevalent.12
The publication of non-industry-sponsored studies may 
also be suppressed or delayed for various reasons.26 For 
example, a large-scale trial of deworming and vitamin A 
that included one million children in India was completed in 
2005, but was published for the first time many years later in 
2013.27 The results indicated that the deworming program was 
not effective in improving weight gain or reducing mortality, 
which is at odds with policies endorsed by powerful institu-
tions including the World Health Organization, the World 
Bank, and the Gates Foundation. Therefore, the investigators 
spent several years checking the trial data to ensure “the 
credibility of the study.”28
Consequences of publication bias
Publication bias will result in misleading estimates of 
treatment effects and associations between study variables. 
Here the consequences of publication bias are considered 
separately for basic biomedical research, observational 
studies, and clinical trials.
Results of basic medical research are often used to support 
subsequent clinical trials. If the results of basic research are 
falsely positive due to biased selection for publication,29 
subsequent clinical trials may waste limited resources 
and fail to confirm the published results of basic studies.30 
For example, publication bias may be used to explain the 
observed discrepancy in results between animal studies 
and clinical trials regarding the neuroprotective efficacy of 
nicotinamide for focal cerebral ischemia.31
Results of observational studies are often highly contra-
dictory over a wide range of health risk factors,32 which may 
be partly due to publication bias. For example, publication 
bias may cause highly contradictory results observed in early 
published studies of genetic associations.33
Publication bias in clinical trials has a direct impact on 
patients’ and populations’ health. When the relative efficacy 
of a treatment is overestimated because of publication bias, 
health resources can be wasted by purchasing more expensive 
interventions, instead of cheaper alternatives, without cor-
responding improvement in outcome. There are also many 
reported cases in which patients have received ineffective or 
harmful treatments.3 For example, biased reporting of trial 
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results delayed the detection of increased mortality risk of 
rofecoxib for Alzheimer’s disease and cognitive impairment, 
and more than 80 million patients had used rofecoxib before 
its withdrawal in 2004.34
How do we measure  
publication bias?
The observation of disproportionately frequent positive find-
ings in published studies and larger effect sizes in smaller 
studies could be used indirectly to estimate the extent of 
publication bias. More convincing evidence on publication 
bias was from studies that compared published and unpub-
lished studies, and studies that followed up cohorts of studies 
from their inception.
High proportion of positive findings  
in published studies
Sterling in 1959 suspected that nonsignificant results might 
be underreported because the results of 97% of psycho-
logical studies published in four journals were statistically 
significant,35 and the same author in 1995 concluded that the 
practices leading to publication bias in psychological research 
had not changed over a period of 30 years.36 The reported 
proportion of published studies with positive outcomes was 
80% in emergency or general medicine,37 53%–72% of trials 
of anesthesiology,38 82% in dental journals,39 and 50%–76% 
in studies of complementary and alternative medicine.40 
However, the proportion of significant results in published 
studies tells us nothing about the proportion of significant 
results in unpublished studies.
Comparing published  
with unpublished studies
Publication bias can be directly detected by comparing 
published results and unpublished results from studies that 
investigate the same research question. If both published and 
unpublished results are available in a meta-analysis, the dif-
ference between the two could be compared to estimate the 
extent of publication bias. For example, data from published 
trials of selective serotonin-reuptake inhibitors indicated 
favorable risk–benefit profile for children with depression, 
but data from unpublished trials of paroxetine, sertraline, and 
citalopram suggested that risks could outweigh benefits in 
children and young people.41 However, it is usually impos-
sible to be certain about whether there are any unpublished 
results and how many remain unpublished. Even if we 
know of the existence of unpublished results, it is still very 
difficult, or even impossible, to obtain unpublished data.
Following up cohorts of studies
A cohort of studies can be tracked from before their 
formal publication and the odds of publication compared 
between studies with different results. For example, studies 
approved by a research ethics committee or institutional 
review board were followed up to investigate the extent 
of publication bias.42,43
A systematic review of publication bias included studies 
that tracked a cohort of studies and reported the rate of 
publication by results.44 The included cohort studies were 
separated into four categories: inception cohorts that followed 
up a cohort of studies from the beginning, regulatory cohorts 
that followed up studies submitted to regulatory authorities, 
abstract cohorts that investigated the full publication of 
meeting abstracts, and manuscript cohorts that reported the 
publication of manuscripts submitted to journals. In this 
meta-analysis, study results were classified as “statistically 
significant” versus “nonsignificant,” and “positive” versus 
“nonpositive.” Positive results may have been defined 
differently in studies of publication bias, including 
“significant,” “favorable,” “important,” or “confirmatory” 
results. The meta-analysis results confirmed that studies with 
statistically significant or positive results were more likely 
to be formally published than those with nonsignificant or 
nonpositive results (Figure 3). The meta-analysis results 
also suggested that the biased selection for publication by 
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Figure 3 Results of a meta-analysis of cohort studies on publication bias. Odds 
ratio .1 indicates that studies with statistically significant or positive results were 
more likely to be formally published than those with nonsignificant or nonpositive 
results (data from Song et al 200944).
Abbreviation: Ci, confidence interval.
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results occurred before the submission of manuscripts to 
journals.44
Cohorts of trial protocols were also used to estimate 
the extent of outcome-reporting bias. Chan and colleagues 
compared reported outcomes and unreported outcomes 
by following up a cohort of 102 protocols of randomized 
controlled trials (RCTs) approved by the Danish Research 
Ethics Committee from 1994 to 199512 and a cohort of 
48 RCT protocols approved by the Canadian Institutes 
of Health Research from 1990 to 1998.13 They found that 
31%–50% of efficacy outcomes and 59%–65% of harm 
outcomes were incompletely reported, and statistically 
nonsignificant outcomes were more likely to be incompletely 
reported than statistically significant outcomes.12,13
Funnel plot and related methods
Because smaller studies have larger random errors, the results 
of smaller studies are more widely spread around the average 
estimate compared to the results of larger studies. If there is 
no publication bias, a plot of sample size against estimated 
effect size from primary studies in a meta-analysis should 
be shaped like a funnel (Figure 4).
Light and Pillemer in 1984 recommended that a funnel 
plot could be used to estimate the risk of publication bias in 
meta-analyses.45 When the true treatment effect equals zero, the 
biased selection of studies with significant results will produce 
a funnel plot with an empty area around zero (Figure 5A). 
When the true effect size is small or moderate, the funnel 
plot may become asymmetric because of publication bias 
(Figure 5B). The use of funnel plots for detecting publication 
bias is also based on an assumption that larger-scale studies are 
less vulnerable to publication bias than smaller studies.
Many statistical methods have been developed to test 
funnel-plot asymmetry. It is hoped that statistical methods 
may provide a more objective and accurate assessment of 
funnel-plot asymmetry than subjective visual assessment. 
However, all available statistical tests have important limita-
tions, and different statistical methods often lead to different 
conclusions about funnel-plot asymmetry.3 The performance 
of tests for funnel-plot asymmetry is particularly poor when 
the number of studies is small and heterogeneity is large in 
meta-analysis.46 It has been recommended that the tests for 
funnel-plot asymmetry should not be used in meta-analyses 
that include fewer than ten studies.47
There are many important limitations of funnel plots 
for detecting publication bias. A sufficiently large number 
of studies with varying sizes is required, and the shape of 
a funnel plot may be subject to different interpretations. 
Because of the relatively small number of studies in typical 
meta-analyses, statistical tests may fail to detect funnel-plot 
asymmetry even if it exists. Most importantly, a skewed 
funnel plot may be caused by factors other than publica-
tion bias, including clinically meaningful heterogeneity, 
poor methodological design of small studies, inadequate 
analysis, fraud, choice of effect measures, and chance.48 An 
asymmetric funnel plot may reveal “small-study effects” by 
indicating that smaller studies tend to report larger effect 
sizes. However, the observed “small-study effects” may not 
necessarily be caused by publication bias.47 For example, 
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Figure 4 Funnel-plot illustration with sufficient number of nonbiased studies. Each 
point represents a study in a meta-analysis.
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Figure 5 (A and B) The possible impact of publication bias on the shape of funnel 
plots. (A) when the true effect size is zero; (B) when the true effect size is small 
or moderate.
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data from a systematic review of calcium supplementation 
for the prevention of pr-eclampsia49 could be used to produce 
a significantly asymmetric funnel plot (Figure 6). However, 
this asymmetric funnel plot may be at least partly explained 
by different baseline risk of hypertension and differences in 
dietary calcium intake between smaller and larger studies in 
this systematic review.49
How to avoid publication bias?
There are a number of steps that may be taken to reduce the 
risk of publication bias. The choice of strategy depends on 
whether the aim is to tackle entire sets of missing studies, or 
whether selective/incomplete reporting of data by authors is 
considered to be the primary problem. Equally, unavailability 
of large chunks of data may arise from journal or editorial 
policies regarding novelty of the manuscript as well as restric-
tions on page length of printed articles. Hence, any attempts 
to reduce the overall burden of publication bias will have to 
adopt a multipronged approach that includes trial registration 
and changes in the current publication model.
identifying and including  
unpublished studies
Locating unpublished studies and unpublished outcomes of 
published studies for inclusion within a systematic review 
may help to reduce publication bias, providing a better 
estimate of effectiveness or association. Detailed advice 
on searching for both published and unpublished studies 
can be found in the Cochrane handbook.50 Searching for 
unpublished studies increased from 35% of efficacy reviews 
in 1996 to 61% in 2006.51 However, locating unpublished 
studies can be difficult and time-consuming. It is never clear 
that all unpublished studies have been located, and it may be 
impossible to access data from an unpublished study even 
if its existence is discovered. Additionally, the discovered 
studies may not be representative of the results or biases of 
the full set of unpublished studies.
A basic strategy that can be used within systematic 
reviews to locate missing or unpublished outcomes of 
published studies is to conduct electronic searches without 
limiting by outcome terms. This is a good strategy in any 
case, as outcomes not found to be statistically significant 
are often not reported in abstracts or represented by index-
ing (MeSH) terms, even when those outcomes are reported 
in full in the main text of the paper.50 To find unpublished 
outcomes, studies that appear appropriate in terms of their 
population, intervention (or exposure), comparison, and 
methodology are collected as full text regardless of outcomes 
reported, provisionally included, and study authors contacted 
to provide details of their outcomes (or any review outcomes 
additional to those provided in the published paper). Where 
trial-registration details are found, this can help reviewers 
to know when unpublished outcomes exist, and to ask for 
them with more authority, but it can be productive to ask 
even without this information. In a recent systematic review 
of RCTs, we established contact with authors of 19 trials, 
and included additional outcomes for twelve studies (of the 
42 included RCTs).52 However a further twelve trials had 
clearly measured but not reported at least one outcome of 
interest for our review (or reported insufficiently to use in 
the meta-analysis, eg, by saying that there was no effect of 
the intervention on an outcome, without providing numerical 
data, or omitting variance data).
Methods for locating unpublished studies also need to be 
built into reviews. These can include searching trial registers 
for completed and ongoing studies (see the next section), 
searching informal publication sources including meeting 
abstracts (included within Cochrane trial registers) and PhD 
theses, searching regulatory bodies (such as the US Food and 
Drug Administration (FDA) database), contacting the authors 
of included studies, and contacting pharmaceutical or medi-
cal device companies for further studies. Data retrieved this 
way can be in the form of complete manuscripts, simple data 
tables, answers to specific queries, study protocols, and/or 
full data sets from completed studies. One Cochrane review 
was updated, including highly detailed FDA regulatory com-
ments and reviews that allowed the researchers to include data 
from 25 studies, but they found they could not use data from 
a further 42 studies where discrepancies in the regulatory 
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Figure 6 An example of a funnel plot of risk ratio (on log scale) against inverse 
of standard error, data from Hofmeyr et al, 2006.49 Statistical testing of funnel-
plot asymmetry: Peters test, P = 0.009, Harbord’s test, P = 0.000 (by using STATA 
“metabias” command).
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data were unresolved, or insufficient data were provided 
by pharmaceutical companies that conducted the trials.53 
Hart et al added unpublished FDA data to already-conducted 
meta-analyses and found that the additional studies reduced 
the effect size in 46% of the 42 outcomes.54
While searching for and including unpublished studies 
and outcomes in systematic reviews is probably important 
in reducing if not eliminating publication bias, there have 
been suggestions that in some circumstances, including 
unpublished studies may increase publication bias. Ferguson 
and Brannick examined 91 meta-analyses of psychological 
interventions, and found that while 63% had tried to find 
unpublished studies, inclusion of unpublished studies did not 
reduce the likelihood of publication bias, and even increased 
it.55 They suggested that this might be due to selection bias 
in unpublished studies, resulting from review authors being 
overrepresented as study authors of the unpublished trials. 
However, the methodology of this analysis has been chal-
lenged on several counts: their definition of unpublished stud-
ies was unusual. Additionally, their analyses found increased 
heterogeneity when “unpublished” studies were included, 
and they interpreted this as an increase in bias, but this may 
simply be confirmation that unpublished studies provide 
different effect sizes than published studies.56
Another important mechanism for reducing the impact 
of publication bias is to keep systematic reviews regularly 
updated. This is useful, as it ensures that the results of stud-
ies whose publication is delayed (often due to having less 
favorable results) and later larger trials are built into the 
review.3 An analysis of unpublished studies within Cochrane 
reviews found that 38% of unpublished studies were eventu-
ally published, but their earlier inclusion would have reduced 
time-lag bias.57
Prospective registration of trials  
and its limitations
Trial registration is a process by which details about the 
design and conduct of a clinical trial are published (in an 
agreed format) in a publicly available resource, which typi-
cally is a website registry, ideally before study recruitment 
begins. A wide range of international trial registries can 
be searched through a single portal, such as the metaReg-
ister of Controlled Trials (http://www.controlled-trials.
com/mrct/mrct_about). Trial registration is considered to 
have both scientific and ethical implications, particularly 
in light of item 19 in the Declaration of Helsinki, which 
states “Every clinical trial must be registered in a publicly 
accessible database before recruitment of the first subject” 
(http://www.wma.net/en/30publications/10policies/b3/
index.html). The WHO recognizes the importance of trial 
registration in enabling health care decisions to be based on 
a collection of all available evidence (http://www.who.int/
ictrp/trial_reg/en/index.html). Other potential benefits of 
registration include the ability to identify gaps while avoid-
ing duplication of research, and the facilitation of participant 
recruitment as well as collaboration amongst researchers 
working in the same area. In theory, trial registration should 
reduce the possibility of entire studies disappearing off the 
radar, or of never emerging in the first place. However, it 
must be recognized that there is no foolproof method of 
rigorously policing and enforcing registration, and there are 
a number of other issues and limitations that have subse-
quently been reported in empirical evaluations. Here, it is 
also worth noting that the initial aims of the trial registries 
were to enable easy identification of trials, and there were no 
specific requirements for detailed descriptions of methods, 
statistical techniques, or outcomes.
The potential lack of methodological detail in registered 
trials has been assessed recently by Reveiz et al, who 
compiled a cohort of 265 ongoing RCTs from seven registries 
accessed through the WHO portal.58 Using the components 
from the Cochrane risk-of-bias tool, the researchers found 
that key items related to randomization, ie, sequence 
generation or allocation concealment was seldom detailed. 
Reveiz et al identified major deficiencies in three areas, 
with the majority of registered trials failing to report useful 
methodological information on allocation concealment 
(97.9%) and harm (89.5%), as well as lacking detail regarding 
method of blinding (86.2%, after excluding open-label 
RCTs). Conversely, other aspects, such as eligibility criteria, 
primary outcomes, and duration of follow-up, were reported 
more frequently. This may in some respects be related to the 
fields for data entry stipulated by individual trial registries, 
with the Australasian and Indian registries showing higher 
proportions of adequate reporting. While methodological 
details may not be mandatory, the availability of such details 
allows readers to appraise trial validity fully and to judge the 
possibility of bias affecting the results.
It could be argued that additional details and results 
from the registered trial would be accessible in journal 
manuscripts or through direct contact with the registered 
investigators. However, Ross et al found that in a sample 
of 677 completed trials, 311 (46%) had been published and 
indexed within Medline, but of these, only 96 (31%) gave 
a citation within clinicaltrials.gov of a relevant published 
article.59 In the sample of .300 trials with no identifiable 
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publication (despite more than 2 years elapsing since date of 
trial completion), details of study investigators were available 
in only 117 instances, and attempts to contact the investiga-
tors yielded no response from 73 trials, or a response that no 
publication was available in 40 cases. These findings have 
been corroborated by Bourgeois et al who demonstrated 
that 184 of 546 (33.7%) registered drug trials did not have 
published results.60 Hence, while registration procedures 
may have helped facilitate more rapid identification of 
trials, there remains a problem with accessing the results 
(either through direct contact with investigators or through 
the registry/bibliographic database), as well as the lack of 
dissemination of trial findings. This problem may prove 
particularly irksome to systematic reviewers who are able 
to identify relevant trials from registries, but may have no 
means of sourcing the results for their data synthesis.
Systematic reviewers also have to face the challenge of 
making a link between the trial-registration record and a 
journal article. If trial-registration numbers are not rigorously 
reported within the associated journal publications, system-
atic reviewers may run the risk of including certain studies 
twice. A study from the Dutch Cochrane Centre found that 
trial-registration numbers were described in only 166/302 
(55%) of the RCTs published in November 2010 that were 
indexed in Medline.61 Moreover, 39% of the published RCTs 
did not appear to have been registered at all. This creates 
difficulties for reviewers who are attempting to check for 
certain elements of selective outcome reporting by comparing 
registry listings against the subsequent journal publication.
There have also been mixed reports of success in using 
trial registries to detect outcome-reporting biases in published 
articles. Hannink et al looked at 152 RCTs published between 
2007 and 2012 of surgical interventions with prespecified 
primary outcomes, and found that 75/152 (49%) had some 
discrepancy between registered outcomes and the published 
data.62 These seemed to involve the omission or introduction of 
a primary outcome, and may have been related to a bias towards 
reporting statistically significant results in 28% of the papers. 
Huic et al looked at a different sample of 152 RCTs and found 
that the registry entries commonly failed to provide adequate 
description of key secondary outcomes (44.1% of RCTs) or 
primary outcomes (38.8% of RCTs).63 Prevalence of differences 
between the registry entry and the journal publication varied 
depending on the data field of interest, ranging from 13.8% to 
77.6%. However, in a more recent study, Norris et al reported a 
catalog of problems during their attempts to evaluate selective 
outcome or analysis reporting through comparison of registry 
entries and journal reports of trials that had been included in 
systematic reviews of effectiveness.64 Key limitations included 
the aforementioned lack of detail in specification of outcome, 
as well as trial registration taking place after completion of 
studies (between 25% and 50% of the time in this cohort) and 
unavailability of results in the clinicaltrials.gov registry. In 
particular, Norris et al found it difficult to judge whether certain 
new outcomes/analyses found within the journal publications 
had been added post hoc, or whether these were genuinely 
prespecified analyses that had inadvertently been missed due 
to poor data entry in the trial registry.64
Open-access policy and changes  
in publication process
While an open-access policy allows free public access to 
journal articles (either at time of publication or at some point 
6–12 months thereafter), this in itself may have no impact on 
selective publication of results. However, publication bias 
could be reduced if journal editors moved away from the policy 
of giving greater priority to articles that were subjectively 
perceived as having greater novelty or importance, or significant 
findings. Some open access journals (such as PLoS One) focus 
on scientific and technical quality of the manuscript rather than 
novelty, and this may encourage authors to submit reports of 
negative or unexciting results. Equally, there is some value 
from a commitment by certain industry sponsors to provide 
unrestricted access (via Internet registries) to aggregated data 
for all their clinical trials within a stipulated interval after 
study completion.65 It is not clear whether the exact format 
and comprehensiveness of such data will match or exceed 
that provided within journal manuscripts. Finally, journal 
editors can give greater weight to transparency by requiring 
trial protocols to be published as appendices alongside the trial 
report. Intriguingly, the British Medical Journal has taken the 
even more dramatic step of requiring investigators to submit 
full data sets to accompany trials that are published in that 
journal.65 Again, it remains to be seen what detail and depth 
will be available within such data sets, or whether there will be 
a substantial drop in submissions to that journal.
Reporting bias will be avoided if the full data from 
clinical trials can be accessible to researchers and systematic 
reviewers, which will have considerable benefits for patients, 
society, and medical science. However, national and interna-
tional legislation is required in order to achieve data-sharing 
in clinical research.66
Summary and conclusion
Publication bias occurs when results of published studies are 
systematically different from results of unpublished studies. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
78
Song et al
Open Access Journal of Clinical Trials 2013:5
The accessibility of trial results depends on whether, when, 
where, and in what format results of a study are published. The 
term “research-dissemination profile” can be used to describe 
the extent to which study results are accessible, which ranges 
from completely inaccessible to fully accessible. Dissemination 
bias occurs when the dissemination profile of research is associ-
ated with the direction and/or nature of its results.
Empirical evidence indicates the existence of biases 
throughout the whole research-dissemination process, 
including time-lag bias, outcome-reporting bias, gray-
literature bias, full-publication bias, language bias, and citation 
bias. Biased selection for research dissemination is related to 
the commercial and noncommercial interests of investigators, 
research sponsors, peer reviewers, and journal editors. 
Consequences of research-dissemination bias may depend on 
types of research (basic biomedical, observational, or clinical 
studies) and levels of result acceptability. The detrimental 
consequences of publication bias include avoidable suffering 
of patients and waste of limited resources.
The extent of publication bias could be directly measured 
by comparing the results of published and unpublished 
studies, and by comparing the rate of publication of studies 
with different results. More often, we may have to use 
indirect approaches to estimate the risk of publication bias 
in published studies, including the proportion of positive 
findings in published studies or funnel plot and related 
methods. It is particularly important to recognize that 
publication bias is only one of many possible explanations 
for an asymmetric funnel plot in meta-analysis.
Locating unpublished studies and unpublished outcomes of 
published studies for inclusion within a systematic review may 
provide a less biased estimate of effectiveness or association. 
The compulsory registration of all trials at inception is 
an important development in preventing publication bias. 
Since publication bias may creep in at various points from 
decision to submit to a trial registry, selection of outcomes 
for analysis, preparation for submission, and journal editorial 
processes, no single step can be relied upon to overcome 
fully the complex actions involved in publication bias, and a 
multipronged approach is required. Given the potential ethical 
and clinical implications of nonpublication/selective reporting 
of trial results, it would certainly help if ethical approval was 
granted conditional on full disclosure at a later stage. During 
the consent process, patients and healthy participants who 
volunteer in good faith to enter clinical trials also need to be 
informed explicitly whether the findings from the trial will 
or will not be made available on an unrestricted (but fully 
anonymized) basis.
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